AI + Preclinical Powered
Collaborative Drug Discovery
Unifying advanced computation with translational biology to accelerate breakthrough therapies. Partner with us to move from target to IND with speed, precision, and confidence.
Contact Us
Oncogenix BV
Redefining
Precision Drug Discovery &
Development
Oncogenix BV, headquartered in the Netherlands, is a next-generation biotechnology company which combines deep computational biology, advanced wet-lab capabilities, and translational research expertise to accelerate the discovery and development of novel therapies in Oncology, Autoimmune Disorders, and CNS diseases.
Our mission is to build breakthrough therapeutics that address high-unmet clinical needs—while delivering end-to-end preclinical services that empower biotech and pharma innovators worldwide.
Our Vision
To become Europe’s leading innovation hub for AI-enabled drug discovery, mechanistic biology, and translational development—turning complex biological data into clinically meaningful insights and life-changing therapies.
We bridge advanced computation with state-of-the-art preclinical platforms to accelerate the path from discovery to clinic.
Through collaborative science, rigorous validation, and scalable innovation, we empower partners to develop safer, more effective treatments with unprecedented speed and precision.
What We Do
Novel Drug Discovery &
Development
We integrate multi-omics intelligence, mechanistic modelling, and wet-lab validation to drive new programs from idea to IND.
Our capabilities include:
- Target identification & prioritization
- Biomarker discovery & validation
- Hit discovery and hit‑to‑lead optimization
- Efficacy, PK/PD and mechanistic studies
- IND‑enabling preclinical development
We specialize in hard-to-treat cancers, autoimmune conditions, and complex CNS disorders.
AI‑Integrated Mechanistic
Biology Platform
Our cutting-edge data-driven AI platform powers our discovery engine with:
- Multi‑omics patient data mining
- Disease sub‑grouping & stratification
- Novel target prediction
- Drug response modelling
- Rational drug combination design
- Repurposing & Repositioning
Our platform identifies hidden biological drivers and reveals new therapeutic opportunities where conventional approaches fall short.
Advanced Preclinical
Services
As part of our global network, we offer comprehensive in-vitro, in-vivo, and translational services, including:
- 2D/3D assays & organoid models
- Immunology & autoimmune models
- Oncology xenograft & PDX studies
- CNS & neuroinflammation models
- Toxicology & DMPK services
Why Oncogenix BV
Integrated AI +
Wet-Lab Ecosystem
Faster Discovery Cycles,
Higher Predictive
Accuracy
End-to-End
Capabilities
From Molecular
Insights to IND‑Ready
Packages
Focus on High‑
Impact Diseases
Oncology, Autoimmune,
CNS
Collaborative
Approach
Partnering with Biotech,
Pharma & Academic
Institutes
Our Collaboration Model
We bring science, AI, and execution together to convert
innovation into tangible therapeutic value.
Co-Development Partnerships
We collaborate closely with partners to advance drug discovery programs from early target identification through preclinical development. Our co-development model combines your domain expertise with our computational biology, assay development, and wet-lab capabilities to accelerate progress while maintaining full transparency, shared decision-making, and clearly defined milestones.
Joint IP Creation
Our joint IP framework enables fair and transparent ownership of discoveries made together, including novel targets, compounds, and biomarkers. We establish clear IP governance from the start to ensure both parties benefit equitably and can confidently advance, license, or commercialize the resulting innovations.
Risk-Sharing Discovery Models
For high-risk or early-stage programs, we offer shared-risk models that reduce upfront costs and align incentives. Through milestone-based structures or success-linked payments, we help partners pursue promising science while minimizing financial burden and increasing the likelihood of downstream success.
Service-Based Preclinical Programs
Partners can access our preclinical platform through modular service offerings tailored to their needs — from custom assays and organoid models to PK/PD, toxicity, and biomarker studies. This flexible approach allows companies of any size to tap into advanced capabilities without long-term commitment or infrastructure investment.